THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.5]-CMP152 ID: TIP-MED-000422

Tobramycin 0.3% & Ciprofloxacin 0.3% Ophthalmic Drops / Ointment IP

Active Ingredient / Scientific Identity: Tobramycin 0.3% & Ciprofloxacin 0.3% Ophthalmic Drops / Ointment IP • Class: Topical Ophthalmic Beta-Blockers (Timolol), Prostaglandin Analogues (Latanoprost, Travoprost, Bimatoprost), Alpha-2 Agonists (Brimonidine), Carbonic Anhydrase Inhibitors (Dorzolamide, Brinzolamide), Fluoroquinolone Antibiotics (Moxifloxacin), and Artificial Tears (Carboxymethylcellulose / Sodium Hyaluronate)

⚖️ Compare Profile
Generic / Entity NameTobramycin 0.3% & Ciprofloxacin 0.3% Ophthalmic Drops / Ointment IP ([12.5]-CMP152)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassTopical Ophthalmic Beta-Blockers (Timolol), Prostaglandin Analogues (Latanoprost, Travopro
Available Dosage FormsStandard approved strengths (refer to comparative context)
Regulatory ClassificationSchedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register un
Key Warning & Review DateRenal: Dorzolamide and Brinzolamide are excreted unchanged in urine—avoid if CrCl <30 mL/min (risk of systemic metabolic acid
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H1 Prescription Drug (Mandatory Red-Bordere✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Tobramycin 0.3% & Ciprofloxacin 0.3% Ophthalmic Drops / Ointment IP (TIP-MED-000422, Reference Code [12.5]-CMP152) is classified under Ophthalmological & Otic (ENT) Preparations (Ch 12) as a Topical Ophthalmic Beta-Blockers (Timolol), Prostaglandin Analogues (Latanoprost, Travoprost, Bimatoprost), Alpha-2 Agonists (Brimonidine), Carbonic Anhydrase Inhibitors (Dorzolamide, Brinzolamide), Fluoroquinolone Antibiotics (Moxifloxacin), and Artificial Tears (Carboxymethylcellulose / Sodium Hyaluronate). Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register under Rule 65 of Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed per approved Author Decision DEC-12 (Option 12A; from merged HTML [12.21] & Inventory CSV mono-15-6) alongside Dorzolamide 2% / Brinzolamide 1% CAI drops (from merged HTML [12.20], Inventory CSV mono-15-4).
Co-indexed per approved Author Decision DEC-12 (Option 12A; from merged HTML [12.21] & Inventory CSV mono-15-6) alongside Dorzolamide 2% / Brinzolamide 1% CAI drops (from merged HTML [12.20], Inventory CSV mono-15-4).
Dosage Forms & Available Strengths:
Standard approved strengths (refer to comparative context)
Routes: Oral / Parenteral

3. Mechanism of Action & Pharmacodynamics

Co-indexed per approved Author Decision DEC-12 (Option 12A; from merged HTML [12.21] & Inventory CSV mono-15-6) alongside Dorzolamide 2% / Brinzolamide 1% CAI drops (from merged HTML [12.20], Inventory CSV mono-15-4).

4. Therapeutic Indications & Evidence-Supported Uses

  • • Anti-Glaucoma Drops: Reduction of elevated intraocular pressure (IOP) in Primary Open-Angle Glaucoma (POAG) and ocular hypertension (lifelong optic nerve preservation)
  • • Antibiotic Drops (Moxifloxacin 0
  • 5%): Acute bacterial conjunctivitis, corneal ulcer, and pre-/post-cataract surgery endophthalmitis prophylaxis
  • • Ocular Lubricants (CMC): Dry eye syndrome (keratoconjunctivitis sicca), computer/age-related tear instability

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Co-indexed per approved Author Decision DEC-12 (Option 12A; from merged HTML [12.21] & Inventory CSV mono-15-6) alongside Dorzolamide 2% / Brinzolamide 1% CAI drops (from merged HTML [12.20], Inventory CSV mono-15-4).

Administration & Meal Timing: Topical ophthalmic instillation; independent of meals. | Latanoprost / Travoprost / Bimatoprost: Strictly at bedtime (09:00–10:00 PM). Timolol: 8 AM & 8 PM.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Comparative pharmacokinetic profile co-indexed under [12.5].
Metabolism & Biotransformation:
Renal: Dorzolamide and Brinzolamide are excreted unchanged in urine—avoid if CrCl <30 mL/min (risk of systemic metabolic acidosis). Hepatic: Caution with Brimonidine in severe hepatic impairment.
Elimination & Renal Adjustment:
Renal: Dorzolamide and Brinzolamide are excreted unchanged in urine—avoid if CrCl <30 mL/min (risk of systemic metabolic acidosis). Hepatic: Caution with Brimonidine in severe hepatic impairment.
Hepatic Impairment Considerations:
Renal: Dorzolamide and Brinzolamide are excreted unchanged in urine—avoid if CrCl <30 mL/min (risk of systemic metabolic acidosis). Hepatic: Caution with Brimonidine in severe hepatic impairment.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • 1. SYSTEMIC ABSORPTION OF TIMOLOL EYE DROPS ('One Drop of Timolol 0.5% in Each Eye = a 10 mg Oral Beta-Blocker Dose Bypassing Hepatic First-Pass!'): Topical Timolol (and Timolol FDCs like Dorzox-T, Combigan, Ganfort) drains via the nasolacrimal duct directly into the systemic venous circulation without liver breakdown! Timolol eye drops are STRICTLY CONTRAINDICATED in Bronchial Asthma, severe COPD, Sinus Bradycardia (<50 bpm), 2nd/3rd Degree AV Heart Block, and Decompensated Heart Failure! 2. Dorzolamide / Brinzolamide are topical sulfonamides—contraindicated in severe sulfonamide allergy (SJS) and severe renal failure (CrCl <30 mL/min). 3. Never dispense Steroid Eye Drops (Betnesol-N, Ciplox-D, Dexoren-S, Pred Forte) over-the-counter for a red eye—if the patient has a viral Herpes Simplex dendritic ulcer or fungal keratitis, steroid drops cause corneal melting, perforation, and permanent blindness!

Key Clinical Precautions: Renal: Dorzolamide and Brinzolamide are excreted unchanged in urine—avoid if CrCl <30 mL/min (risk of systemic metabolic acidosis). Hepatic: Caution with Brimonidine in severe hepatic impairment.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • • Latanoprost/Bimatoprost: Conjunctival hyperaemia (harmless mild eye redness in first weeks), eyelash lengthening/thickening (hypertrichosis), irreversible darkening of iris pigment and periorbital eyelid skin (wipe excess drop off cheek immediately!). • Timolol: Ocular stinging, systemic bradycardia, bronchospasm, masked hypoglycaemia. • Dorzolamide: Bitter metallic taste in the back of the throat 5 minutes after instillation! • Brimonidine: Ocular allergic conjunctivitis, dry mouth, drowsiness.
  • Fatal Acute Bronchospasm in Asthmatics or Complete Heart Block / Syncope in Elderly Cardiac Patients from Timolol Eye Drops! Steroid-induced glaucoma and cataract from unsupervised use of steroid-antibiotic ('-D') eye drops.
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • Topical Timolol + Oral Beta-Blockers (Metoprolol, Atenolol, Bisoprolol), Verapamil, Diltiazem, Digoxin, or Amiodarone: Causes severe additive systemic bradycardia, heart block, and orthostatic falls! Brimonidine + TCAs/MAOIs or CNS depressants (additive sedation)

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [12.5].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: Mandatory 5-Step Eye-Drop Technique for CGHS Patients: 1. The '2-Minute Nasolacrimal Occlusion' Rule: Immediately after placing 1 drop into the lower eyelid pocket, close your eyes gently (do not blink or squeeze tightly!) and press your index finger against the inner corner of the eye (next to the bridge of the nose) for 2 FULL MINUTES! This blocks the tear duct so the medicine stays in the eye (+50% efficacy) and prevents Timolol from entering the throat/bloodstream (-70% systemic heart/lung side effects!). 2. The '5-Minute Gap' Between Multiple Drops: If prescribed 2 or 3 different eye drops (e.g., post-cataract antibiotic + steroid + lubricant), wait at least 5 minutes between each bottle—putting the second drop in immediately washes the first drop straight out of the eye! Always apply thicker eye gels/ointments LAST (10 minutes after liquid drops). 3. Storage & 28-Day Discard Rule: Unopened Latanoprost bottles must be stored in the refrigerator (2°C–8°C); once opened, most eye drops must be discarded 28 to 30 days after opening (write the opening date on the label!). Never touch the dropper tip to eyelashes or fingers.
    • Meal & Clock Timing Instruction: Topical ophthalmic instillation; independent of meals. (Latanoprost / Travoprost / Bimatoprost: Strictly at bedtime (09:00–10:00 PM). Timolol: 8 AM & 8 PM.)
    • Missed Dose Protocol: Instil 1 drop as soon as remembered unless close to the next scheduled drop; never instil 2 drops at once (the human conjunctival sac holds only ~20–30 microlitres— less than 1 single drop—so a second drop simply overflows down the cheek or drains into the bloodstream!).
    • Geriatric Dispensing Pearl: Many elderly CGHS patients with asthma or heart block forget to mention their glaucoma eye drops when visiting the physician because they do not consider eye drops 'real medicine'—always ask about eye drops during medication reconciliation and check for hidden Timolol inside FDC bottles (Ganfort, Combigan, Dorzox-T)!

    Storage, Stability & Dispensing Safeguards: COLD CHAIN MANDATORY (2°C–8°C): Store in a pharmaceutical refrigerator between 2°C and 8°C; DO NOT FREEZE. Protect from light and heat during dispensing.

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.